Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHA) Profit After Tax (2019 - 2025)

Historic Profit After Tax for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to -$24.2 million.

  • Innate Pharma's Profit After Tax rose 940.26% to -$24.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$24.2 million, marking a year-over-year increase of 7415.26%. This contributed to the annual value of -$52.9 million for FY2024, which is 54905.28% down from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Profit After Tax is -$24.2 million, which was up 940.26% from -$52.9 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Profit After Tax ranged from a high of $618509.0 in Q2 2023 and a low of -$60.4 million during Q4 2021
  • Over the past 5 years, Innate Pharma's median Profit After Tax value was -$27.6 million (recorded in 2021), while the average stood at -$32.4 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first soared by 9972.36% in 2021, then crashed by 441166.67% in 2024.
  • Quarter analysis of 5 years shows Innate Pharma's Profit After Tax stood at -$60.4 million in 2021, then rose by 1.87% to -$59.3 million in 2022, then soared by 86.26% to -$8.1 million in 2023, then crashed by 549.05% to -$52.9 million in 2024, then soared by 54.3% to -$24.2 million in 2025.
  • Its last three reported values are -$24.2 million in Q2 2025, -$52.9 million for Q4 2024, and -$26.7 million during Q2 2024.